Company news

Chugai Pharmaceutical Co., Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Supplementary Materials Consolidated Financial Statements for the nine months ended September 30, 2026 (IFRS)

October 27, 2026

CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the nine months ended September 30, 2026)

October 27, 2026

F. Hoffmann-La Roche Announces Third Quarter Sales 2026

October 22, 2026

Notice Regarding Discontinuation of Development of GYM329 (emugrobart) for Obesity, Return of License and Resumption of Development for SMA

September 28, 2026

Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors

September 9, 2026

Chugai and GSK Sign Exclusive License Agreement for Anti-Dengue Virus Antibody AID351

August 18, 2026

Chugai Announces 2026 2nd Quarter Results

July 27, 2026

CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the six months ended June 30, 2026)

July 24, 2026

F. Hoffmann-La Roche Announces Half Year Results 2026

July 23, 2026

Chugai Files New Drug Application in Japan for Sparsentan for the Treatment of IgA Nephropathy

June 22, 2026

Chugai Receives The Imperial Invention Prize, the Highest Honor of the FY2026 National Commendation for Invention, Recycling Antibody Technology Recognized for its Contribution to Pharmaceutical Research

May 26, 2026

Chugai Pharmaceutical: Alecensa Receives the World-First Tumor-Agnostic Approval for ALK Fusion Gene-Positive Solid Tumors Across Adult and Pediatric Patients

May 18, 2026

Chugai Pharmaceutical Obtains Approval for FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Alecensa for ALK Fusion Gene-Positive Solid Tumors

May 18, 2026

Q1 Results (Jan-Mar 2026)

April 24, 2026

Announcement of Termination of Co-Promotion of Rituxan® in Japan (Anti-CD20 Monoclonal Antibody)

April 9, 2026

Mitsubishi Electric Announces Director Candidates

March 30, 2026

Voting Results (Extraordinary Report) of the 115th Annual General Meeting of Shareholders

March 27, 2026

Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

March 26, 2026

Chugai Pharmaceutical - Notice Regarding Discontinuation of Development of GYM329 in Spinal Muscular Atrophy and Facioscapulohumeral Muscular Dystrophy

March 24, 2026

Chugai Pharmaceutical Obtains Regulatory Approval for Lunsumio and Polivy Combination Therapy for Additional Indication of Relapsed or Refractory Large B-cell Lymphoma

March 23, 2026

Notice Regarding Discontinuation of Development of GYM329 (Emugrobart) in Spinal Muscular Atrophy (SMA) and Facioscapulohumeral Muscular Dystrophy (FSHD)

March 22, 2026

Chugai Pharmaceutical Files for the Medical Device Component of the Port Delivery Platform with ranibizumab in Japan

March 19, 2026

Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

February 24, 2026

Chugai Pharmaceutical Launches “ELEVIDYS” as Japan’s First Regenerative Medical Product for Duchenne Muscular Dystrophy

February 19, 2026

Anti-CD20 Monoclonal Antibody Rituxan® Approved for Treatment of Autoimmune Hemolytic Anemia

February 19, 2026

NXT007 Suggests Favorable Tolerability and Efficacy in Phase I/II Study for Hemophilia A Following Direct Switch from Emicizumab without Washout Period

February 9, 2026

Full Year Results (Jan-Dec 2025)

January 29, 2026

Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

November 6, 2025

Renalys Pharma to be Acquired by Chugai Pharmaceutical

October 24, 2025

Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors

October 23, 2025

RANI: Chugai Deal Announced

October 20, 2025

Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing

October 17, 2025

Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity

August 26, 2025

Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update

August 7, 2025

Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity

August 7, 2025

Chugai Pharma Taiwan Honored at the AREA 2025 for its Social Empowerment and Green Innovation

August 3, 2025

Chugai and Gero Enter into Joint Research and License Agreement to Develop Novel Therapies for Age-Related Diseases

July 7, 2025

Calls

The 5 newest of 9 calls. Every call is listed under its year.

Decks

The 5 newest of 55 decks. Every deck is listed under its year.